{
  "version": "v1",
  "updated_at": "2026-01-19",
  "notes": "Authoritative blend registry. Each blend references component peptides by slug.",
  "blends": [
    {
      "slug": "glow",
      "display_name": "GLOW",
      "components": [
        "bpc-157",
        "tb-500",
        "ghk-cu"
      ],
      "taxonomy_keys": [
        "regenerative_blend"
      ]
    },
    {
      "slug": "klow",
      "display_name": "KLOW",
      "components": [
        "bpc-157",
        "tb-500",
        "ghk-cu",
        "kpv"
      ],
      "taxonomy_keys": [
        "regenerative_blend"
      ]
    },
    {
      "slug": "bpc-157-tb-500",
      "display_name": "BPC-157 / TB-500",
      "components": [
        "bpc-157",
        "tb-500"
      ],
      "taxonomy_keys": [
        "regenerative_blend"
      ]
    },
    {
      "slug": "cjc-ipamorelin",
      "display_name": "CJC-1295 / Ipamorelin",
      "components": [
        "cjc-1295",
        "ipamorelin"
      ],
      "taxonomy_keys": [
        "gh_axis_blend"
      ]
    },
    {
      "slug": "cagri-sema",
      "display_name": "Cagrilintide / Semaglutide",
      "components": [
        "cagrilintide",
        "semaglutide"
      ],
      "taxonomy_keys": [
        "metabolic_weight_blend"
      ],
      "components_unresolved": []
    },
    {
      "slug": "glp3-reta",
      "display_name": "GLP-3 RETA (Quad Agonist Class)",
      "components": [
        "retatrutide"
      ],
      "taxonomy_keys": [
        "metabolic_weight_blend"
      ],
      "components_unresolved": []
    },
    {
      "slug": "glp2-trz",
      "display_name": "GLP-2 TRZ",
      "components": [
        "tirzepatide"
      ],
      "taxonomy_keys": [
        "metabolic_weight_blend"
      ],
      "components_unresolved": []
    },
    {
      "slug": "glp1-sma",
      "display_name": "GLP-1 SMA",
      "components": [
        "semaglutide"
      ],
      "taxonomy_keys": [
        "metabolic_weight_blend"
      ],
      "components_unresolved": [
        "amylin"
      ]
    }
  ],
  "blend": {
    "sections": {
      "overview": [
        {
          "title": "What this blend is",
          "text": "This blend page explains why people pair components, what overlap exists, what tradeoffs show up in the real world, and where uncertainty is highest."
        }
      ],
      "use_cases": [
        {
          "title": "Use cases (real-world)",
          "text": "Use cases are framed as intent + context, not as a recommendation."
        },
        {
          "text": "People usually consider blends when they’re trying to simplify decision-making, stack fewer vials, or chase a combined effect profile. The downside is more moving parts and more uncertainty."
        },
        {
          "text": "If one component would be a bad fit for you (meds, history, side effects), the blend is also a bad fit — even if the other component seems appealing."
        }
      ],
      "interaction_summary": [
        {
          "title": "Interaction summary",
          "text": "Interaction flags are category prompts — not dosing instructions."
        },
        {
          "text": "Blends inherit interaction risk from every component. If one component has a meaningful interaction class, treat the blend as having that interaction class."
        },
        {
          "text": "If you’re on prescription meds (especially cardio, anticoagulant/antiplatelet, serotonergic, immunomodulating), treat uncertainty as a reason to slow down and verify with a clinician."
        }
      ]
    }
  }
}
